Introduction to TRK-950 Anti-CAPRIN-1 Therapy

TRK-950 anti-CAPRIN-1 therapy is emerging as a novel approach for treating advanced solid tumors. This first-in-class humanized antibody specifically targets CAPRIN-1, a cytoplasmic phosphoprotein. While normal cells do not express CAPRIN-1 on their surface, most solid tumors show high membrane expression. This specificity allows TRK-950 to engage immune cells to attack cancer cells while sparing healthy tissue. Recently, researchers conducted a Phase I study in Japan to assess the safety and tolerability of this agent.

Clinical Efficacy of TRK-950 Anti-CAPRIN-1 Therapy

The Phase I trial enrolled thirteen patients with advanced solid tumors to evaluate TRK-950 as both a monotherapy and in combination with nivolumab. In the monotherapy phase, patients received 5 or 10 mg/kg weekly. The combination phase used 10 mg/kg weekly or 20 mg/kg biweekly alongside nivolumab. Notably, the investigators observed no dose-limiting toxicities during the study. Most adverse events were manageable, including pyrexia, nausea, and elevated alanine aminotransferase. Consequently, the researchers determined that the drug is well-tolerated in Japanese patients.

Furthermore, the study provided early signals of clinical benefit. One patient with melanoma achieved a partial response that researchers tracked over an extended period. Although no responses occurred in the combination cohort, the safety profile remains encouraging for future development. Because of these results, TRK-950 is now moving into Phase II trials. These subsequent studies will specifically focus on patients with gastric cancer and melanoma to further validate the antitumor potential of this target.

Future Outlook for CAPRIN-1 Targeting

The discovery of CAPRIN-1 as a universal cancer target opens new doors for immunotherapy. Since the protein appears on the membrane of cancer stem cells and metastatic cells, targeting it may prevent recurrence. Moreover, TRK-950 demonstrated a linear pharmacokinetic profile, which simplifies dosing strategies for clinicians. As ongoing Phase II trials progress, oncology specialists anticipate more data on the long-term efficacy of TRK-950 anti-CAPRIN-1 therapy across various tumor types.

Frequently Asked Questions

What is the mechanism of action for TRK-950?

TRK-950 is a humanized monoclonal antibody that binds to CAPRIN-1 on the surface of cancer cells. It induces antitumor effects by engaging immune cells to destroy the targeted tumor cells.

What were the most common side effects reported in the Phase I study?

The most frequent adverse events included pyrexia, nausea, constipation, and increased alanine aminotransferase (ALT). Importantly, researchers reported that these events were not dose-dependent.

Is TRK-950 currently available for clinical use in India?

No, TRK-950 is currently in the clinical trial phase. It is undergoing Phase II evaluation in countries like Japan and the United States for melanoma and gastric cancer.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Koyama T et al. A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors. Invest New Drugs. 2026 Apr 14. doi: 10.1007/s10637-026-01609-z. PMID: 41979863.

2. Okano F, et al. Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950. Cancer Res Commun. 2023;3(4):654-668. doi: 10.1158/2767-9764.CRC-22-0310.

3. Toray Industries, Inc. Toray Initiating Phase II Clinical Trials with TRK-950 for Gastric Cancer Patients. Published August 30, 2023. Available at: https://www.toray.com